Sugi Predict

Sugi Predict / Compounds / SCHEMBL1006809

SCHEMBL1006809

SCHEMBL1006809

CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3cc(Cl)ccc3nc2-1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TOP1 P11387 18/20 1.00
▸ MEN1 O00255 3/20 0.82
▸ KMT2A Q03164 3/20 0.82
▸ SMN1; SMN2 Q16637 3/20 0.82
▸ KDM4E B2RXH2 3/20 0.82
▸ ALDH1A1 P00352 3/20 0.82
▸ CYP3A4 P08684 2/20 0.82
▸ HBB P68871 2/20 0.82
▸ CASP1 P29466 1/20 0.82
▸ CASP7 P55210 1/20 0.82
▸ TP53 P04637 2/20 0.79
▸ GLA P06280 2/20 0.79
▸ HPGD P15428 2/20 0.79
▸ STAT6 P42226 1/20 0.79
▸ CHEK1 O14757 1/20 0.79
▸ HDAC3 O15379 1/20 0.79
▸ ABCC4 O15439 1/20 0.79
▸ GMNN O75496 1/20 0.79
▸ LMNA P02545 1/20 0.79
▸ CYP1A2 P05177 1/20 0.79

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27502805 1.00 TOP1 (1.00) TOP1MEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL8322065 0.93 TOP1 (0.87) TOP1MEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL28535745 0.90 TOP1 (0.83) TOP1MEN1KMT2ASMN1; SMN2KDM4E
Hydroxycamptothecin SCHEMBL25875 0.90 TOP1 (1.00) TOP1MEN1KMT2ASMN1; SMN2KDM4E
Hydroxycamptothecin SCHEMBL29929278 0.90 TOP1 (1.00) TOP1MEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL1007394 0.90 TOP1 (1.00) TOP1MEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL1005975 0.90 TOP1 (1.00) TOP1MEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL17145878 0.90 TOP1 (1.00) TOP1MEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL12343943 0.90 TOP1 (1.00) TOP1MEN1KMT2ASMN1; SMN2KDM4E
Hydroxycamptothecin SCHEMBL9384413 0.90 TOP1 (1.00) TOP1MEN1KMT2ASMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1556010-A4 PHARMACEUTICAL FORMULATIONS TARGETING SPECIFIC REGIONS OF THE GASTROINTESTINAL TRACT SUPERGEN INC (US) 2007-12-05 — — EP claimed
WO-2007095389-A2 TREATMENT OF HYPERPROLIFERATIVE DISEASES WITH CAMPTOTHECINE N-OXIDE AND ANALOGS NOVACEA, INC. (US) 2007-08-23 — — WO claimed
EP-1556010-A2 PHARMACEUTICAL FORMULATIONS TARGETING SPECIFIC REGIONS OF THE GASTROINTESTINAL TRACT SuperGen, Inc. (US) 2005-07-27 — — EP claimed
US-20040162263-A1 Pharmaceutical formulations targeting specific regions of the gastrointesinal tract SUPERGEN, INC., A DELAWARE CORPORATION 2004-08-19 — — US claimed
WO-2004041195-A2 PHARMACEUTICAL FORMULATIONS TARGETING SPECIFIC REGIONS OF THE GASTROINTESTINAL TRACT SUPERGEN, INC. (US) 2004-05-21 — — WO claimed
EP-1365705-A1 INJECTABLE PHARMACEUTICAL COMPOSITION COMPRISING MICROPARTICLES OR MICRODROPLETS OF CAMPTOTHECIN SuperGen, Inc. (US) 2003-12-03 — — EP claimed
EP-1311266-A2 COMBINATION HIV THERAPY INCLUDING CAMPTOTHECIN SuperGen, Inc. (US) 2003-05-21 — — EP claimed
US-6534080-B2 Injecting into a patientaqueous suspension of solid particles suitable for intravenous delivery, the solid particles comprising a camptothecin, and a 0.3 nm to 3.0 mu m thick layer of a membrane-forming amphipathic lipid SUPER GEN, INC. 2003-03-18 — — US claimed
US-6509027-B2 Anticancer agent SUPERGEN, INC. 2003-01-21 — — US claimed
US-6497896-B2 AQUEOUS SUSPENSION; THERMAL STERILIZATION SUPERGEN, INC. 2002-12-24 — — US claimed
US-20020150615-A1 Injectable pharmaceutical composition comprising microdroplets of a camptothecin SKYEPHARMA AG (CH) 2002-10-17 — — US claimed
US-20020146460-A1 Method for administering camptothecins VIA injection of pharmaceutical composition comprising coated particles of a camptothecin ASTEX PHARMACEUTICALS, INC. 2002-10-10 — — US claimed
US-20020147202-A1 Method for administering camptothecins via injection of a pharmaceutical composition comprising microdroplets containing a camptothecin RTP PHARMA INC. (CA) 2002-10-10 — — US claimed
US-20020142048-A1 Injectable pharmaceutical composition comprising coated particles of camptothecin ASTEX PHARMACEUTICALS, INC. 2002-10-03 — — US claimed
WO-2002064064-A1 INJECTABLE PHARMACEUTICAL COMPOSITION COMPRISING MICROPARTICLES OR MICRODROPLETS OF CAMPTOTHECIN SUPERGEN, INC. (US) 2002-08-22 — — WO claimed
WO-2002000168-A2 COMBINATION HIV THERAPY INCLUDING CAMPTOTHECIN SUPERGEN, INC. (US) 2002-01-03 — — WO claimed
US-11672776-B2 Multi-arm polymeric alkanoate conjugates NEKTAR THERAPEUTICS (US) 2023-06-13 — — US disclosed
US-10463659-B2 Multi-arm polymer prodrugs NEKTAR THERAPEUTICS (US) 2019-11-05 — — US disclosed
US-4473692-A Camptothecin derivatives and process for preparing same KABUSHIKI KAISHA YAKULT HONSHA (JP) 1984-09-25 — — US disclosed
EP-0074256-A1 Camptothecin derivatives, processes for preparing same, formulations containing such derivatives and their use KABUSHIKI KAISHA YAKULT HONSHA (JP) 1983-03-16 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11672776-B2 Multi-arm polymeric alkanoate conjugates ALK, ALKBH3, PAICS TOP1 161/4885MEN1 3463/4885KMT2A 723/4885
US-10463659-B2 Multi-arm polymer prodrugs PAICS, CD38, ENTPD1 TOP1 747/4885MEN1 2709/4885KMT2A 1565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.